Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2121

Sort by

Sort Order Select

Journal Articles

TLR8 gain of function: a tall surprise

Bertrand Boisson, Jean-Laurent Casanova

Blood (2021) 137 (18): 2420–2422.

https://doi.org/10.1182/blood.2020010463

Published: 2021

Journal Articles

Common variable immune deficiency: case studies

Charlotte Cunningham-Rundles

Blood (2019) 134 (21): 1787–1795.

https://doi.org/10.1182/blood.2019002062

Published: 2019

Journal Articles

Carbon Dots As a Potential Therapeutic Agent for Anemia Treatment in Malignancies

Yuanlin Xu, Boyang Wang, Huan Zhang, Xiaoli Qu, Mingming Zhang, Xiuli An, Siyu Lu, Shijie Zhang

Blood (2019) 134 (Supplement_1): 941.

https://doi.org/10.1182/blood-2019-130971

Published: 2019

Journal Articles

Management Algorithms for Gaucher Disease Type 1 in Saudi Arabia: A Consensus Result from a National Meeting

Ayman Alhejazi, MD, Abdul Kareem Almomen, MD, Ahmad M Tarawah, Ahmed M AlSuliman, Hussain H. Al Saeed, MBBS, MD, Mahsen AlSaleh, MD, Ohoud F Kashari, Marwan Elbagoury, MSc, Omar Hussein

Blood (2019) 134 (Supplement_1): 4864.

https://doi.org/10.1182/blood-2019-122822

Published: 2019

Journal Articles

Real-World Analysis of Ruxolitinib Treatment Patterns and Outcomes Among Patients with Myelofibrosis

Tanya Burton, Kejal Parikh, Manish Patel, Kevin Sundquist, Lincy S. Lal, Ronda Copher, Aaron T. Gerds, MD MS

Blood (2019) 134 (Supplement_1): 4750.

https://doi.org/10.1182/blood-2019-124651

Published: 2019

Journal Articles

Metformin Suppress Cellular and Molecular Processes Related to Maintenance and Proliferation of Myeloproliferative Neoplasm Stem Cell

Juan L Coelho-Silva, BSc, MSc, Thiago Mantello Bianco, MSc, Antonio Bruno Alves Silva, BSc, Diego Antonio Pereira-Martins, M.Sc., Natasha Peixoto Fonseca, B.Sc., M.Sc., Isabel Weinhäuser, MSc, Eduardo M Rego, MD PhD, Fernando Chahud, MD PhD, João Agostinho Machado-Neto, PhD, Lorena Lobo Figueiredo-Pontes, MD PhD, Fabiola Traina, MD PhD

Blood (2019) 134 (Supplement_1): 1682.

https://doi.org/10.1182/blood-2019-132115

Published: 2019

Journal Articles

Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF)

Mirko Farina, MD, Simona Bernardi, PhD, Nicola Polverelli, Camilla Zanaglio, PhD, Michele Malagola, MD, Federica Re, Federica Cattina, MD PhD, Mariella D'Adda, MD, Giuseppe Rossi, Tatiana Zollner, MD, Andrew Dunbar, MD, Ross L. Levine, MD, Domenico Russo, MD

Blood (2019) 134 (Supplement_1): 1684.

https://doi.org/10.1182/blood-2019-127451

Published: 2019

Journal Articles

The Infection-Driven Production/Secretion of Inflammatory Cytokines By Circulating Monocytes of Myelofibrosis Is Defective and Is Reactivated after In Vivo JAK1/2 Inhibition

Martina Barone, PhD, Francesca Ricci, BS, Marco Romano, PhD, Dorian Forte, PhD, Giuseppe Auteri, MD, Francesco Fabbri, PhD, Emanuela Ottaviani, Pierluigi Tazzari, MD, Nicola Vianelli, MD, Giovanni Martinelli, MD, Michele Cavo, Francesca Palandri, PhD MD, Lucia Catani

Blood (2019) 134 (Supplement_1): 1686.

https://doi.org/10.1182/blood-2019-127322

Published: 2019

Journal Articles

Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis

Blood (2019) 134 (Supplement_1): 1656.

https://doi.org/10.1182/blood-2019-130691

Published: 2019

Journal Articles

Plasma EDA Fibronectin in Primary Myelofibrosis Correlates with Bone Marrow Fibrosis and Predicts Splenomegaly

Alessandro Malara, PhD, Cristian Gruppi, PhD, Margherita Massa, Vittorio Rosti, MD, Giovanni Barosi, Alessandra Balduini, MD

Blood (2019) 134 (Supplement_1): 1688.

https://doi.org/10.1182/blood-2019-130735

Published: 2019

Journal Articles

Splenic CD24 low Red Pulp Macrophages Provide an Alternate Niche for Chronic Myeloid Leukemia Stem Cells

Michael A Amrein, MD PhD, Elias D Bührer, MD PhD, Stefan Forster, MD, Stephan Isringhausen, Christian M Schürch, MD PhD, Salil S. Bhate, MMath, Mohamad Al Sayed, PhD, Cesar Nombela Arrieta, PhD, Ramin Radpour, PhD, Carsten Riether, PhD, Adrian F Ochsenbein, MD

Blood (2019) 134 (Supplement_1): 1634.

https://doi.org/10.1182/blood-2019-126593

Published: 2019

Journal Articles

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Chiara Paoli, PhD, Paola Guglielmelli, MD PhD, Francesco Mannelli, MD, Lara Mannelli, MD, Vittorio Rosti, MD, Maria Chiara Finazzi, MD, Elisa Rumi, MD, Marco Ruggeri, Alessandro Pancrazzi, PhD, Carmela Mannarelli, PhD, Guido Finazzi, MD, Maria Luisa Ferrari, BSc, Laura Lissandrini, BSc, Duccio Fantoni, RN, Giovanni Barosi, Mario Cazzola, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 1662.

https://doi.org/10.1182/blood-2019-122837

Published: 2019

Journal Articles

Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naïve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib

Ruben A Mesa, MD, John Catalano, MBBS, FRACP, FRCPA, Francisco Cervantes, MD, Timothy Devos, MD PhD, Jason Gotlib, MD MS, Jean-Jacques Kiladjian, MD PhD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, Kazuya Shimoda, MD PhD, Elisabeth Coart, PhD, Koenraad D'Hollander, MD MSC, Rafe Donahue, PhD, Mark M Kowalski, MD PhD

Blood (2019) 134 (Supplement_1): 1663.

https://doi.org/10.1182/blood-2019-122506

Published: 2019

Journal Articles

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

Sean Bujarski, BA, Kyle Udd, BA, Camilia Soof, BS, Tanya M. Spektor, PhD, Tahmineh Safaie, Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Joshua Stern, Cathy S. Wang, BS, Ning Xu, PhD, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, BS, Eric Souther, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 1786.

https://doi.org/10.1182/blood-2019-132012

Published: 2019

Journal Articles

JAK2V617F-Mediated Endothelial Dysfunction Promotes Congestive Heart Failure in a Murine Model of Myeloproliferative Neoplasm

Melissa Castiglione, BS, Christopher Mazzeo, BS, Ya-Ping Jiang, Juei-Suei Chen, Wei Yin, Richard Lin, Huichun Zhan, MD

Blood (2019) 134 (Supplement_1): 7.

https://doi.org/10.1182/blood-2019-131372

Published: 2019

Journal Articles

Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

Guldane Cengiz Seval, Atilla Uslu, MD, Ekin Kircali, Sinem Civriz Bozdag, MD, Klara Dalva, MD, Selami Kocak Toprak, MD, Meltem Kurt Yuksel, MD, Pervin Topcuoglu, MD, Isinsu Kuzu, Onder Arslan, Muhit Özcan, Taner Demirer, MD, Osman Ilhan, MD, Hamdi Akan, MD, Meral Beksac, MD, Gunhan Gurman, MD

Blood (2019) 134 (Supplement_1): 2019.

https://doi.org/10.1182/blood-2019-128750

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation Combined with Mesenchymal Stem Cells Transfusion in Primary Myelofibrosis-a Single-Center Retrospective Study

Qingyuan Wang, MD, Limin Liu, MD PhD, Huifen Zhou, Miao Miao, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 2054.

https://doi.org/10.1182/blood-2019-130572

Published: 2019

Journal Articles

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Shien Guo, PhD, Weiqin Liao, MS, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 2207.

https://doi.org/10.1182/blood-2019-129386

Published: 2019

Journal Articles

Bone Marrow Plasma Cell Burden in Gaucher Disease Correlates with Local Macrophage Infiltration and May be Altered By Disease Treatment

Monika Klimkowska, MD PhD, Maciej J. Machaczka, MD PhD

Blood (2019) 134 (Supplement_1): 3593.

https://doi.org/10.1182/blood-2019-131343

Published: 2019

Journal Articles

Generation and Characterisation of KY1066, a Fully Human Antibody Targeting the Enzymatic Activity of Matriptase-2 for the Treatment of Iron Overload in Beta Thalassemia

Matthew Wake, PhD, Jonathan Papworth, BSc, Luke Bayliss, BSc, Benjamin Grimshaw, PhD, Natalie Rynkiewicz, PhD, Jemima Paterson, BSc, Alicia Poindron, MSc, Erin Spearing, Emily Carter, Robyne Hudson, BSc, Verena Petzer, MD, Amelie Largounez, BSc, Audrey Belot, BSc, Anais Palin, BSc, Igor Theurl, MD PhD, Volker Germaschewski, Delphine Meynard, PhD

Blood (2019) 134 (Supplement_1): 3532.

https://doi.org/10.1182/blood-2019-124075

Published: 2019

NARROW

TLR8 gain of function: a tall surprise

Common variable immune deficiency: case studies

Carbon Dots As a Potential Therapeutic Agent for Anemia Treatment in Malignancies

Management Algorithms for Gaucher Disease Type 1 in Saudi Arabia: A Consensus Result from a National Meeting

Real-World Analysis of Ruxolitinib Treatment Patterns and Outcomes Among Patients with Myelofibrosis

Metformin Suppress Cellular and Molecular Processes Related to Maintenance and Proliferation of Myeloproliferative Neoplasm Stem Cell

Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF)

The Infection-Driven Production/Secretion of Inflammatory Cytokines By Circulating Monocytes of Myelofibrosis Is Defective and Is Reactivated after In Vivo JAK1/2 Inhibition

Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis

Plasma EDA Fibronectin in Primary Myelofibrosis Correlates with Bone Marrow Fibrosis and Predicts Splenomegaly

Splenic CD24 low Red Pulp Macrophages Provide an Alternate Niche for Chronic Myeloid Leukemia Stem Cells

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naïve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

JAK2V617F-Mediated Endothelial Dysfunction Promotes Congestive Heart Failure in a Murine Model of Myeloproliferative Neoplasm

Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

Allogeneic Stem Cell Transplantation Combined with Mesenchymal Stem Cells Transfusion in Primary Myelofibrosis-a Single-Center Retrospective Study

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Bone Marrow Plasma Cell Burden in Gaucher Disease Correlates with Local Macrophage Infiltration and May be Altered By Disease Treatment

Generation and Characterisation of KY1066, a Fully Human Antibody Targeting the Enzymatic Activity of Matriptase-2 for the Treatment of Iron Overload in Beta Thalassemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only